ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryRiehenYmmunobio AG
Ymmunobio AG Logo
Verified· 3 sources

Ymmunobio AG

Summary

About the company

The core activity of Ymmunobio is the development of preclinical cancer therapeutics, particularly antibodies that influence the immune system and directly inhibit cancer cells. The company focuses on developing innovative treatments for cancer patients, especially for solid tumors, and has already made progress in developing antibodies that reactivate the immune system and directly inhibit cancer cells.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered8
Antibody-based cancer therapies for solid tumors
Antibody-based therapies for solid tumors, focusing on first-in-class programmes against NPTXR and on hard-to-treat tumour types.
Antibody-Drug-Conjugates (ADC)
Dual-payload anti-NPTXR ADCs with a 4+4 linker–payload architecture, designed for precise tumour targeting and cytotoxic payload delivery; programme YB-811 in the preclinical stage.
Radiopharmaceuticals (RPT)
NPTXR-targeted radiopharmaceuticals for imaging and therapy with 177Lu and 161Tb, including RPT-Dx and RPT-Tx; programmes YB-830, YB-831 and YB-832.
Bi-specific T-cell engagers (BiTCE)
Bi-specific T-cell engagers that redirect T cells to NPTXR-positive tumours and enable selective immune-mediated tumour cell killing; programmes YB-820 and YB-821.
Tri-specific T-cell engagers (TriTCE)
Tri-specific T-cell engagers with an aCD3 and aCD28 component for T-cell activation against NPTXR-positive tumours; programme YB-880 in the lead-optimization stage.
Press

Media

October 16, 2023Media
Industry leaders to take startups to new heights
startupticker.ch

Knowledge

No knowledge articles yet

Once Ymmunobio AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Ymmunobio AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Ymmunobio AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Ymmunobio AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Gartengasse 12
4125 Riehen

At a glance

Legal form
Corporation
UID
CHE-468.419.785
Founded
2021 · 5 years
Last commercial register change
February 29, 2024
Employees
21 to 50

Similar companies

TT
TOLREMO therapeutics AG
Basel
MP
Mepha Pharma AG
Basel
ST
Synendos Therapeutics AG
Basel
TT
TargImmune Therapeutics AG
Basel